Yes, but what's the aducanumab angle?
Yesterday brought the unsurprising news that a pair of amyloid-targeting treatments for Alzheimer’s disease failed in a clinical trial. But in 2020, virtually all news in Alzheimer’s is filtered through the lens of Biogen and its controversial treatment. So we asked: What does this mean for aducanumab?
The answer, depending on whom you asked, is basically this: The latest failures certainly don’t amount to good news. The study in question, called DIAN, was specifically engineered to avoid the amyloid stumbling blocks of the past.
At the same time, experts pointed out, DIAN was different from Biogen’s supporting studies, which enrolled thousands of early-stage Alzheimer’s patients regardless of their genetic status.
Read more.
The answer, depending on whom you asked, is basically this: The latest failures certainly don’t amount to good news. The study in question, called DIAN, was specifically engineered to avoid the amyloid stumbling blocks of the past.
At the same time, experts pointed out, DIAN was different from Biogen’s supporting studies, which enrolled thousands of early-stage Alzheimer’s patients regardless of their genetic status.
Read more.
.png)
No hay comentarios:
Publicar un comentario